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Tumour-induced bone disease is the major cause of morbidity in
patients with multiple myeloma (MM) (Salmon and Cassady,
1993). The changes range from osteoporosis-like bone loss to the
development of osteolytic lesions and frank hypercalcaemia
(Salmon and Cassady, 1993; Malpas, 1995; Coleman, 1997). The
process leading to MM-induced bone disease is based on a
complex interplay of tumour cells, of cells of the bone marrow
microenvironment and of bone matrix proteins. The initial step
during the development of MM-induced bone disease is the
homing of the myeloma cells in the bone marrow (Teoh and
Anderson, 1997), which involves the interactions between adhe-
sion molecules expressed on the cell surface of the tumour cells
(e.g., the b integrins) and their receptors on cellular and non-
cellular bone marrow elements (Teoh and Anderson, 1997; Van
Riet et al, 1998). Adhesion of MM cells to cells of the bone
marrow microenvironment triggers the secretion of cytokines
(e.g., interleukin-6) by MM-cells and bone marrow stromal cells,
which in turn increases the expression of adhesion molecules
(Uchiyama et al, 1993). Interleukin-6 not only stimulates myeloma
cell growth, but, like other cytokines (e.g., tumour necrosis factor
and interleukin-1), is also responsible for the recruitment, differen-
tiation and activation of osteoclasts (Bataille et al, 1997). The
increased activity of osteoclasts together with the progressive
decrease in the activity of bone-forming cells subsequently leads
to MM-induced bone destruction (Bataille et al, 1989). 
The evaluation of the degree of bone involvement in MM and in
monoclonal gammopathies of undetermined significance (MGUS,
plasma cell dyscrasias which evolve into malignant lymphoplas-
mocytic diseases in approximately one third of cases (Bladé and
Kyle, 1995) could be important for clinical guidance (Bataille
et al, 1986), but is limited by the invasiveness of the presently
available standard method, the quantitative bone histology. This
problem has been partly overcome by the quantification of
biochemical markers of bone turnover, such as osteocalcin as a
marker of bone formation (Bataille et al, 1990) and the degrada-
tion products of type I collagen as indexes of bone resorption
(Elomaa et al, 1992; Pecherstorfer et al, 1997). We have recently
shown that serum levels of circulating bone sialoprotein (BSP)
also reflect bone turnover (Woitge et al 1999; Seibel et al, 1996).
BSP is a phosphorylated 70–80 kDa glycoprotein that accounts for
5–10% of the non-collagenous bone matrix (Fisher et al, 1983;
Heinegard and Oldberg, 1989). The protein is a major synthetic
product of active osteo- and odontoblasts and contains an Arg-
Gly-Asp (RGD) sequence (Chen et al, 1991; Fujisawa et al, 1993;
Shapiro et al, 1993). This sequence is recognized by various int-
egrin receptors including the arb3 vitronectin receptor (CD51/CD61)
(Oldberg et al, 1988; Ross et al, 1993), which is expressed by
osteoclasts (Ross et al, 1993). Thus, in the course of normal bone
remodelling, BSP is likely to be involved in the adhesion of bone
resorbing cells to the extracellular bone matrix (Helfrich et al,
1992). Although preferentially detected in the cells of mineralized
tissues (Fisher et al, 1983; Chen et al, 1991; Shapiro et al, 1993),
BSP has been found to be ectopically expressed in the cytoplasma
and on the surface of myeloma cells (Bellahcène et al, 1996b) and
of tumour cells of other malignancies (Bellahcène et al, 1994). In
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with the appearance of bone metastases, suggesting that BSP may
be involved in the molecular mechanisms responsible for cancer
cell osteotropism (Bellahcène et al, 1996a; Diel et al, 1999). 
Employing a recently developed radioimmunoassay
(Karmatschek et al, 1997), the present study was carried out to
evaluate the diagnostic and prognostic importance of serum BSP
levels in MM and in MGUS. Healthy adults and patients with
benign vertebral osteoporosis were included as control groups. 
SUBJECTS AND METHODS 
Subjects 
A total of 318 individuals was included in the study. In all subjects,
a complete history and physical exam was taken at the time of
sample collection. The following groups were studied (Table 1). 
Healthy adults 
The control group comprised of an ambulatory population of 139
subjects without any evidence of skeletal or non-skeletal disease.
All women in this group were postmenopausal with a mean dura-
tion of menopause ( ISD) of 13.2 I 9.7 years (median: 11.5 years,
range: 1–30 years). All subjects had radiographs of the lumbar and
thoracic spine (Multiplanimat Siemens, Erlangen, Germany).
Bone mineral density was determined in an anterior-posterior posi-
tion at the lumbar spine by dual X-ray absorptiometry (QDR 1000,
Hologic, Waltham, MA). Subjects with vertebral fractures, a bone
mineral density of less than 2 SD of the age- and sex-matched mean,
significant degenerative disease of the spine, or abnormal labora-
tory results, were excluded. None of the controls was taking any
medication known to affect bone metabolism, including bisphos-
phonates, glucocorticoids, HRT, osteotropic vitamins or calcium
supplements. 
Patients with multiple myeloma (MM) 
62 patients with MM were enrolled in the study. All patients were
studied at diagnosis of MM. Prior to study entry, none of the
patients had been treated with chemotherapy, radiotherapy, gluco-
corticoids, or bisphosphonates. The diagnosis of MM was based
on i) the percentage of plasma cells in the bone marrow, ii) the
presence of monoclonal protein in serum or urine, iii) the radio-
logical evidence of bone involvement. In all subjects, plain
radiographs were taken of the skull, spine, pelvis and of painful
regions outside the axial skeleton. Bone marrow biopsies were
performed by Yamshidi technique. In all patients, serum creatinine
was less than 4 mg dl–1. Patients were followed over 4 years, with
a median observation time of 427 days (range: 1–1550 days).
Staging was performed according to Durie and Salmon (1975).
At the time of diagnosis, 14 patients (23%) presented with stage I,
15 patients (24%) with stage II, and 33 patients (53%) with stage
III disease. One patient with stage I, 2 patients with stage II, and 6
patients with stage III disease had serum creatinine levels of
³2 mg dl–1 (substage B). For further analyses, patients were sub-
classified according to bone disease: i) no bone disease; ii) osteo-
porosis-like bone loss with or without pathological fractures; iii)
osteolysis with or without pathological fractures; and iv)
hypercalcaemia. 
A protocol including vincristin, melphalan, cyclophosphamide,
and prednisolone was applied in the majority of patients, except
for 3 cases with indolent stage I MM and one patient who refused
cytostatic treatment. None of the patients achieved a complete
remission, i.e. a complete disappearance of the paraprotein as
detected by immunofixation. 21 patients had sequential measure-
ments on bone turnover markers and were included in the analyses
of therapeutic monitoring. 
Patients with monoclonal gammopathy of undetermined
significance (MGUS) 
46 patients with MGUS were included in the present study. All
patients underwent plain X-ray examination of the skull, spine and
pelvis, and bone biopsies were performed in Yamshidi technique.
For diagnosis of MGUS and differentation to MM, the criteria of
Salmon and Cassady were applied (Salmon and Cassady, 1993).
As shown earlier, bone resorption rates in patients with smoldering
myeloma do not differ from those in patients fulfilling strict 
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Table 1 Population characteristics at baseline (median (range)) 
Healthy adults MM MGUS OPO 
Sex (M/F)* 69/70 26/36 20/26 23/48 
Age (years) 64 (37–83) 68 (28–90) 66 (40–86) 67 (40–92) 
No bone disease* – 9 29 – 
O’po* – 34 16 71 
O’ly* – 40 – – 
S-Cr (mg dl–1) 0.9 (0.6–1.3) 1.0 (0.41–3.9)b 0.95 (0.7–1.7)e 0.9 (0.5–1.8)f 
S-Ca (mM l–1) 2.4 (2.16–2.65) 2.37 (1.99–3.52) 2.35 (1.93–3.09) 2.39 (2.12–2.67)
U-Ca (mM mM–1 Cr) 0.25 (0.02–1.29) 0.45 (0.01–23.4)a 0.35 (0.04–3.11) 0.42 (0.04–1.30)
b2 (mg ml–1) 1.7 (1.2–3.3) 4.15 (1.4–16.3)c 1.9 (0.9–6.3)f 1.6 (1.0–7.6)f 
t-Prot (mg dl–1) 7.3 (6.6–8.2) 9.2 (5.7–14.3)a 7.6 (6.2–9.7) 7.3 (6.2–8.3)
CRP (mg l–1) 5.0 (5.0–50) 8.6 (5.0–100)a 5.0 (5.0–157) 5.0 (5.0–26)f 
S-Fer (mg l–1) 112 (10–699) 190 (10–2315)b 95 (8–586)e 97 (10–843)d 
Hb (g dl–1) 13.4 (11.1–15.6) 11.05 (5.1–16.5)c 13.7 (10.9–16.5)f 13.9 (11.1–17.2)a,f 
MP (%) n.d. 36 (0–65.7) 18.5 (8.3–39.5)f n.d. 
PCC (%) n.d. 40 (0–95) 5 (0–20)f n.d. 
*Number of patients. aP < 0.05, b P < 0.01, cP < 0.001 vs. healthy adults. d P < 0.05, eP < 0.01, fP < 0.001 vs. MM. 
Abbreviations: MM, multiple myeloma; MGUS, monoclonal gammopathy of undetermined significance; OPO; primary vertebral osteoporosis; M, males; F,
females; O’po, osteoporosis-like bone involvement; O’ly, osteolysis; S-Cr, serum creatinine; S-Ca, serum calcium; U-Ca, urinary calcium; b2, b2-microglobulin in
serum; t-Prot, total protein; CRP, C-reactive protein; S-Fer, serum ferritin; Hb, haemoglobin; MP, monoclonal protein in serum (% of total serum protein); PCC,
plasma cell content of the bone marrow; n.d., not detected. 346 HW Woitge et al 
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diagnostic criteria for MGUS (Bataille et al, 1996). We therefore
included 5 patients in the MGUS group who were diagnosed with
smoldering myeloma. The plasma cell content in these patients
was higher than in the MGUS patients (>10% and <30% of nucle-
ated cells), but none of them presented with anaemia, renal failure,
or osteolytic bone lesions. 
Patients with vertebral osteoporosis (OPO) 
71 patients with newly diagnosed and untreated osteoporosis were
included. Of the 48 women in this group, all were post-
menopausal with a median duration of menopause of 18 years
(range: 2–41 years). The diagnosis of OPO was based upon the
presence of at least one vertebral fracture (wedge, compression,
or biconcave) that was not attributable to adequate spinal trauma,
plus a lumbar bone mineral density below 2.5 SD of the age- and
sex-matched mean. None of the subjects in this group had a
history of malignant disease, nor were there any signs of plasma
cell dyscrasia or secondary osteoporosis. At the time of study
enrollment, all patients had normal renal and hepatic function,
and none was given any medication known to interfere with bone
turnover, including bisphosphonates, glucocorticoids, hormone
replacement therapy, osteotropic vitamins or calcium supple-
mentation. 
Laboratory analyses 
Blood and urine samples were obtained simultaneously between 8
and 11 a.m. with subjects having had their usual breakfast. Venous
blood was collected in vacutainers without additive, allowed to
clot for 30 to 45 minutes at room temperature, and centrifuged at
1000 g for 10 minutes. Serum aliquots were stored at 280˚C.
Urine samples were spot urines. Urinary creatinine (Cr) was deter-
mined immediately after sample collection, and a second aliquot
was stored at –30˚C until analysis. 
Routine biochemistry was performed in all participants,
including RBC, WBL, serum calcium, creatinine, g-glutamyl
transpeptidase, albumin, b2-microglobulin, and serum and urine
electrophoresis. No dietary restrictions were applied. 
Determination of bone sialoprotein in serum 
Serum immunoreactive bone sialoprotein (BSP) was quantified by
a new radioimmunoassay (RIA) described elsewhere (Karmatschek
et al, 1997). In brief, BSP was isolated from human bone by stan-
dard extraction procedures (Fisher et al, 1987) and final purification
was achieved by wide pore reversed-phase HPLC using a Latek C4
150 ´ 4 mm 300 A column and 0.13% heptafluorobutyric acid as
eluant. Antibodies against human BSP were then raised in chicken
and purified by affinity chromatography. For the determination
of BSP in serum, 100 ml of 125I-labelled bone sialoprotein
(1.5 ng ml–1) and 100ml of the chicken-anti-human-BSP-antibody
(1:200 dilution) were added to an equal volume of serum, control
sample, or standard, respectively. This mixture was incubated for
24 h at 4˚C, after which 100 ml l of a donkey-anti-chicken-IgG
(1:150 dilution) were added as a second antibody. Following
another incubation step (2 h, 4˚C), the antibody-bound radioac-
tivity was centrifuged for 10 minutes at 2000 g, and the super-
natant was discarded. The radioactive pellet was then washed with
250 ml of an aqueous buffer (60 g l–1 polyethylene glycol, 9 g l–1
NaCl) and centrifuged for 10 minutes, after which the supernatant
was discarded. Radioactivity was measured in a Beckmann -
gcounter for 1 min, and results were calculated by interpolation of
the unknown samples with a point-to-point curve fitting equation
of the standards. The coefficients of variation were 7.0% for intra-
(n = 20) and 9.1% for interassay variability (n = 10). The lower
detection limit in the present RIA was 0.7 ng ml–1. Spiking of
human samples with purified BSP resulted in a mean recovery of
99.4% (range: 92–108%). 
Determination of urinary pyridinium crosslinks 
Total urinary pyridinoline (PYD) and deoxypyridinoline (DPD)
were determined by HPLC after acid hydrolysis of the urine
(Black et al, 1988). Following partition chromatography on a CF1
cellulose column, pyridinium crosslinks of samples and external
standards were separated by reverse-phase ion-paired HPLC, and
the eluting crosslink compounds were quantified by fluorometry.
The overall reproducibility of this assay was 8–12% including the
partitioning step. Values were expressed relative to urinary creati-
nine (Cr) levels. 
Determination of serum osteocalcin 
Serum osteocalcin (OC) was measured by a commercial
immunoassay (LUMItest® Osteocalcin, BRAHMS Diagnostica,
Berlin, FRG). Coefficients of variation, as assessed in our laborat-
ory, were 6% for intra- (n = 20) and 9% for inter-assay variability
(n = 10). 
Statistical analyses 
The SAS software package was used for statistical analysis.
Descriptive values are presented as median and range unless other-
wise stated. Z scores are expressed as standard deviation of the
age- and sex-adjusted mean of healthy adults according to: z = 
(x - mean)/SD. Linear regression analysis was performed to assess
the correlations between markers. Group differences were deter-
mined using Student’s t-test for parametric and Wilcoxon’s rank-
sum test for non-parametric variables. Fisher’s exact test was used
to test for differences in the distribution of patients within cate-
gories. Sex specific receiver operating characteristic (ROC)
analyses were used to examine the diagnostic validity of the
various markers. The association of variables to survival was
determined by applying the Cox proportional hazards model, first
univariately followed by a stepwise multivariate regression
analysis. Survival rates, measured from the date of first diagnosis
to death or last follow-up, were estimated using Kaplan-Meier
analyses, and the logrank test was applied for detection of differ-
ences in survival curves. All statistical tests were two-tailed and a
probability level of less than 0.05 was considered statistically
significant. 
RESULTS 
Comparison of healthy controls and patients with MM,
MGUS, or OPO 
Median levels of serum BSP and of urinary PYD and DPD were
significantly higher in patients with MM, MGUS and OPO than in
normal controls (Table 2). Compared to healthy controls, median
serum OC levels were significantly elevated only in patients with
MM and OPO. Patients with MM had significantly higher levels of
BSP, PYD and DPD than patients with MGUS or OPO. No signif-
icant differences in serum levels of OC were found among the 3
groups of patients. 73% of patients with MM had serum levels of BSP above the
upper limit of the normal range as compared to 48% of MGUS
patients and 27% of patients with OPO. For the other markers, the
proportion of patients with abnormally high values ranged from
30% to 50% in MM, from 4% to 14% in MGUS and from 10% to
13% in OPO (Table 2). 
All 3 patients who showed a transformation from MGUS into
overt MM during follow-up (after 19, 20 and 31 months, respectively)
presented with initially elevated serum levels of BSP (21.0 ng
ml–1, 21.6 ng ml–1 and 50.7 ng ml–1, respectively). In contrast, the
levels of PYD, DPD and OC of these patients were within normal
range at the time of the first diagnosis of MGUS. 
Differentiation of MM patients from healthy adults and
patients with MGUS or OPO 
With regard to the differentiation between healthy subjects and
patients with MM, results of ROC analyses were similar for serum
BSP and the urinary crosslinks, whereas a clearly discrepant curve
was obtained for serum OC (Figure 1A). For serum BSP, the area
under the curve (AUC) was 0.922, and for urinary PYD and DPD
0.895 and 0.882, respectively. At a chosen specificity of 80%,
serum BSP had a sensitivity of 87.5%, and similar values were
seen at a specificity of 95%. In contrast, serum OC was not useful
in distinguishing between healthy individuals and tumour patients
(AUC: 0.502). At a specificity of 80%, this marker had a sens-
itivity of less than 40%. A similar but less pronounced pattern of
results was noted when patients with MM were compared to
patients with MGUS (Figure 1B) or OPO (Figure 1C). 
Effect of the tumour stage and of the extent of bone
disease on biochemical markers of bone metabolism 
When MM patients were stratified according to the staging system
of Durie and Salmon, patients with stage II and stage III disease
had significantly higher serum levels of BSP than patients with
stage I disease (P < 0.01) and healthy controls (P < 0.001). In
patients with stage I disease, BSP levels were also elevated
compared to healthy controls (P < 0.001). BSP levels in patients
with stage II disease did not differ from those with stage III
disease. Compared to healthy controls, urinary PYD and DPD
were higher in MM patients with stage II (P < 0.01) and stage III
disease (P < 0.01), but not stage I disease. Urinary DPD levels
were significantly higher in patients with stage III disease than in
patients with stage I disease (P < 0.05). Serum levels of OC did not
differ among the 3 stages (Figure 2). 
Stratification according to the extent of neoplastic bone involve-
ment, as judged from plain radiographs and the measurement of
serum calcium, revealed a similar pattern for serum BSP and the
urinary crosslinks (Figure 3): Hypercalcaemic patients and normo-
calcaemic patients with overt osteolysis had significantly higher
levels of all 3 markers than healthy adults (P < 0.01) and patients
with MGUS (P < 0.03). Normocalcaemic MM patients with osteo-
porosis-like changes and MM patients without radiologically
evident bone destruction had significantly higher values of serum
BSP (P < 0.01) and urinary DPD (P < 0.05) compared to healthy
adults, but no significant differences were detected when com-
pared to patients with MGUS. Also, no significant differences
were found between MM patients with osteoporosis-like bone loss
and MM patients with lytic lesions for any of the applied markers
of bone turnover (Figure 3). 
Since the differentiation between benign and neoplastic osteo-
porosis-like changes is of particular clinical interest, biochemical
markers of 11 MM patients with osteoporosis-like bone involve-
ment without evidence for lytic lesions were compared with the
corresponding marker levels of 11 age- and sex-matched patients
with benign osteoporosis. Serum BSP and urinary PYD were
significantly higher in the MM group (P < 0.05, respectively). No
significant differences were found for serum OC and urinary DPD. 
Correlations of laboratory parameters in patients with
MM 
Serum concentrations of BSP correlated with serum creatinine 
(r = 0.25, P < 0.05), serum calcium (r = 0.44, P < 0.001), b2-
microglobulin (r = 0.31, P < 0.01), serum ferritin (r = 0.35, 
P < 0.01), haemoglobin (r = 0.26, P < 0.05), and with the plasma
cell infiltration in the bone marrow (r = 0.40, P < 0.001). Of the
other markers of bone turnover, only DPD showed a weak correla-
tion with the plasma cell infiltration in the bone marrow (r = 0.19,
P < 0.05). No other significant correlations were found. Serum b2-
microglobulin was positively associated with serum creatinine 
(r = 0.42, P < 0.001), serum calcium (r = 0.28, P < 0.05), and with
the plasma cell infiltration in the bone marrow (r = 0.50, 
P < 0.001), and showed an inverse correlation with haemoglobin 
(r = 0.43, P < 0.001). Except for PYD and DPD, no significant
correlations were observed among the different biochemical
markers of bone turnover. 
Effect of chemotherapy on serum BSP in patients with
MM 
In 21 patients, markers of bone turnover were reanalysed
following chemotherapy. In all 12 patients with a > 25% decrease
in the monoclonal component, a reduction in serum BSP levels
was found (P < 0.001 vs. baseline; average decrease of BSP:
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Table 2 Biochemical markers of bone turnover in the disease groups (median (range)) 
Healthy adults MM MGUS OPO 
ULN > ULN > ULN > ULN 
BSP (ng ml–1) 10.1 (3.4–27.4) 20.9  27.6 (4.8–120)c 73% 18.6 (3.7–76.1)c,f 48% 15.8 (7.4–82.2)c,f  27%
OC (ng ml–1) 16 (6.9–37.1) 34.4 24 (6.1–134)b 30% 19.1 (4.5–46) 4% 22.6 (12.2–45)a 10% 
PYD (nM mM–1 Cr) 23.8 (9.9–79.7) 50.6  50.7 (15–774)c 50% 27.6 (8.9–63.6)a,e 11% 29.8 (11.4–101)b,e  13% 
DPD (nM mM–1 Cr) 5.5 (2–18.7) 12.0  13.6 (3.9–314)c 57% 6.1 (2.2–21.8)a,e 14% 7.8 (2.7–21.5)b,e 13% 
aP < 0.05, bP < 0.01, cP < 0.001 vs. healthy adults. dP < 0.05, eP < 0.01, fP < 0.001 vs. MM. 
Abbreviations: see Table 1. ULN, upper limit of normal (95% confidence interval); BSP, serum immunoreactive bone sialoprotein; OC, serum osteocalcin; PYD,
urinary pyridinoline; DPD, urinary deoxypyridinolin. 348 HW Woitge et al 
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53%;) after a median observation period of 5 months (range: 1–10
months). In contrast, in patients without a significant response or
an increase in the monoclonal protein, serum BSP levels did not
change significantly after a median observation period of 6 months
(range: 1–7 months) (Figure 4). The proportional change in serum
BSP levels was significantly associated with the proportional
change in monoclonal protein concentrations (r = 0.55, P < 0.001).
Laying down a 50% reduction in BSP levels as response criteria, 8
of the 21 patients achieved a BSP response. All of these patients
showed a > 25% decrease in the monoclonal component, thus,
could be regarded as responders to therapy. In this group, the
change in serum BSP levels was highly correlated with the propor-
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tional change in monoclonal protein concentrations (r = 0.76, 
P < 0.001). Another subanalysis included 10 of the 21 patients
who had follow-up measurements after 6 ± 1 months. 6 of these
patients were responders to therapy with a > 25% decrease in the
monoclonal component and showed a decrease in BSP levels
ranging from 28–58% (median: 51%). In contrast, the 4 non-
responders in this subgroup showed a marginal decrease (<10%)
or even an increase in serum BSP. 
Serum BSP as a prognostic factor in patients with MM 
The probability of survival was significantly greater in the 15
patients with initially normal serum BSP values (≤20.9 ng ml–1)
compared to the 41 patients with BSP values above the normal
range (P < 0.001, logrank test) (Figure 5). When patients were
stratified according to BSP values within or above the normal
range, no statistically significant differences in other clinical and
laboratory values were found (Table 3). Interestingly, in a
subgroup of patients with baseline levels of BSP > 70 ng ml–1
(n = 10), no patient survived the observation period (median
survival time: 92 days). 
Univariate analyses using the Cox proportional hazards model
identified the monoclonal protein (P = 0.0061), b2-microglobulin
(P = 0.0069), the plasma cell content of the bone marrow (P =
0.0073), and serum BSP (P = 0.0126) as prognostic parameters for
shortened survival (Table 4). However, a stepwise multivariate
regression analysis (including all variables with a P value of < 0.1
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Figure 4 Serum BSP before and after chemotherapy. 21 patients were
analysed according to serum BSP levels in response to a VMCP regimen.
The left panel shows the result for the responders (n = 12), i.e. > 25%
decrease in the monoclonal protein, with a median observation period of 5
months (range: 1–10 months). The right panel shows the result for the non-
responders (n = 9), i.e. ≤ 25% or increase in the monoclonal protein, with a
median observation period of 6 months (range: 1–17 months). Small
symbols and dotted lines represent individual values, large symbols (± SD)
and full lines represent the mean of each group 
Table 3 Disease characteristics by BSP levels in patients with MM (median
(range)) 
BSP ≤ 20.9 ng ml–1 (I) BSP >  20.9 ng ml–1 (II) 
Sex (M/F)* 6/9 20/27 
Age (y) 70 (28–90) 67 (39–87) 
Paraproteinaemia 
IgG 80% 78% 
IgA 20% 15% 
Others 0% 7% 
S-Cr (mg dl–1) 1.1 (0.6–3.3) 1.0 (0.41–3.9) 
S-Ca (mM l–1) 2.28 (2.03–2.88) 2.39 (1.99–3.52)P = 0.077 vs. I 
U-Ca (mM mM–1 Cr) 0.33 (0.07–1.02) 0.51 (0.01–23.4)P = 0.086 vs. I 
b2 (mg l–1) 3.8 (1.6–13.4) 4.4 (1.4–16.3)
t-Prot (mg dl–1) 10.1 (5.7–14.2) 8.7 (6.0–14.3) 
CRP (mg dl–1) 0.52 (0.5–10) 0.73 (0.5–7.1) 
S-Fer (mg l–1) 88 (30–1483) 223 (10–2315) 
Hb (g dl–1) 11.3 (7.9–13.8) 11 (5.1–16.5) 
MP (%) 42.8 (17.5–64.7) 35.6 (0–65.7) 
PCC (%) 15 (0–80) 50 (0–95)P = 0.062 vs. I 
*Number of patients. Abbreviations: see Table 1. 
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Figure 5 Probability of survival according to serum BSP. Kaplan-Meier
estimates are shown for the group of patients with serum BSP ≤20.9 ng ml–1
(n = 15, full line) and for the group of patients with serum BSP > 20.9 ng ml–1
(n = 41, dotted line). Differences in the survival probabilities from the time of
diagnosis until death or latest follow-up were estimated using the log rank
test. The median survival times of the two groups are significantly different 
(P < 0.001) 
Table 4 Univariate Cox Proportional Hazards Analysis* 
Variable Coefficient SE c2 P= 
MP 0.0327 0.0121 7.534 0.0061 
b2 0.1174 0.0443 7.299 0.0069 
PCC 0.0180 0.0069 7.208 0.0073 
BSP 0.0135 0.0056 6.219 0.0126 
t-Prot 0.1467 0.0768 3.720 0.0538 
Stagea 0.4550 0.2470 3.521 0.0606 
*Univariate survival analyses were performed for all variables listed in Tables
1 and 2. Only those variables (continuous, except a) are presented that
reached P values of <0.1. Abbreviations: see Table 1. 350 HW Woitge et al 
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in the univariate analysis) revealed that only BSP and the mono-
clonal protein independently contributed to the prediction of
survival (Table 5). Exclusion of 3 cases with indolent stage I MM
from the analyses did not affect the results. 
DISCUSSION 
In the present investigation, MM patients were found to have
significantly higher serum BSP levels than did healthy adults and
patients with MGUS or benign osteoporosis. Our earlier finding
that MM patients present with increased levels of urinary pyri-
dinium crosslinks, which up to now have been regarded as the
most reliable biochemical markers of bone resorption, was
confirmed (Pecherstorfer et al, 1997). In MGUS patients, the
median BSP levels were also significantly elevated when
compared to values in age-and sex-matched healthy adults (48% of
MGUS patients had BSP levels above the upper limit of the
normal range), but did not differ from levels in patients with
benign osteoporosis (Table 1). Previously, Bataille et al showed an
increased bone resorption rate (as assessed by quantitative bone
histology) in 45% of MGUS patients at the time of diagnosis
(Bataille et al, 1996). The authors also noted that the bone resorp-
tion rate at presentation was significantly higher in MGUS patients
who subsequently showed a progression into overt MM than in
MGUS patients with stable disease. In the present study, all 3 indi-
viduals with MGUS that later was found to have transformed into
MM, revealed elevated BSP levels at the time of the first diagnosis
of MGUS. Thus, BSP serum levels may serve as an early marker
of malignant transformation in plasma cell dyscrasias initially
classified as MGUS. 
Serum BSP as well as urinary PYD and DPD were able to
discriminate between patients with MM and healthy controls, as
shown by ROC analysis. Of even greater clinical importance is the
differentiation between tumour-induced and benign osteoporosis.
In this regard, we found that serum BSP and urinary PYD were
significantly higher in a subgroup of patients with MM-induced
osteoporosis-like bone loss than in age- and sex-matched patients
with benign osteoporosis. However, ROC analyses demonstrated
that none of the applied biomarkers of bone turnover had enough
discriminative power (AUC in ROC analysis > 0.9) to differentiate
between MM and OPO. Therefore, it seems unlikely that a single
non-invasive measurement of bone metabolism will be sufficient
to discriminate between benign and malignant bone disease. 
Compared to the urinary pyridinium crosslinks, serum BSP
appears to be more sensitive in reflecting early interactions
between myeloma cells and the bone resorbing cells. While in
stage I myeloma patients PYD and DPD values did not differ from
those in healthy adults, median BSP levels were found to be signif-
icantly higher (Figure 2). This finding could be explained by the
fact that BSP is produced by bone forming cells. The number and
activity of osteoblasts are increased in early stage MM (Bataille et
al, 1991), but become progressively suppressed as the malignant
process progresses (Bataille et al, 1989). Additional BSP may
origin directly from MM cells (Bellahcène et al, 1996b). Thus,
while the urinary pyridinium crosslinks only reflect the amount of
collagen degradation during osteolysis, serum BSP levels may be
influenced by the number and activity of osteoblasts and also by
the number of MM cells and their BSP production rate. The latter
assumption is supported by the significant correlations between
serum BSP levels and two established markers of tumour load: the
serum concentrations of b2-microglobulin and the plasma cell
content of the bone marrow (Salmon and Cassady, 1993). A cor-
relation with the tumour load could not be shown for the urinary
pyridinium crosslinks. 
Following chemotherapy, the significant correlation between
changes in serum BSP concentrations and changes in the mono-
clonal protein further indicates that serum BSP levels reflect tumor
burden. All patients with objective improvement (> 25% reduction
in the monoclonal protein) under the VMCP regimen also showed
a significant reduction in their BSP levels. No such changes were
found for the pyridinium crosslinks (Pecherstorfer et al, 1997). 
We here demonstrate that BSP serum levels at the time of first
diagnosis are negatively associated with the survival time of MM
patients. In a univariate analysis, the serum concentrations of the
monoclonal protein, of b2-microglobulin and of BSP as well as the
plasma cell content of the bone marrow were significant predictors
of the survival time. However, in a subsequent multivariate
analysis only serum BSP and the monoclonal protein were found
to be independent prognostic indices (Table 5). 
In breast and prostate cancer, the expression of BSP has already
been shown to be highly predictive of neoplastic bone involvement
(Bellachène et al, 1996a; Waltregny et al, 1998; Diel et al, 1999).
In these cancers, as well as in myeloma, the interaction between
tumour cells and osteoclasts seems to be pivotal for the growth and
propagation of the neoplastic cell clone in the bone marrow and for
the subsequent bone destruction (Mundy and Yoneda, 1998). BSP
may play a central role in the relationship between MM cells and
osteoclasts. Raynal et al demonstrated that BSP increases bone
resorption in vitro in a dose-dependent manner (Raynal et al,
1996). Therefore, we hypothesize that following the homing of the
MM cells to the bone marrow, the secretion of BSP by the
neoplastic cells increases the bone resorption rate. The release of
BSP and growth factors (e.g., transforming growth factor-b) and
other proteins already present in the bone matrix in turn stimulate
directly or indirectly (via stimulation of other cells of the bone
marrow microenvironment) the proliferation of the tumour cells
(Bataille et al, 1997; Mundy and Yoneda, 1998). It should also be
noted that MM cells have been shown to express an integrin
receptor, i.e. the vitronectin receptor, that binds to the RGD region
of BSP (Van Riet and Van Camp, 1993), although, however, to a
lesser extent than other adhesion molecules such as CD44, VLA-4
and VLA-5, syndecan-1 and NCAM (Van Riet et al, 1998). 
In conclusion, serum BSP levels were significantly increased in
patients with MM and were found to correlate with bone destruc-
tion, tumour mass and overall survival. The measurement of BSP
serum levels is – in contrast to quantitative bone histology – a
noninvasive procedure, which can easily be repeated as required.
The quantification of immunoreactive BSP in serum also seems to
overcome some of the limitation of urinary bone turnover markers,
i.e. the greater technical and biological variability. Serum BSP
may serve as a parameter for quantifying myeloma-induced bone
Table 5 Multivariate Cox Proportional Hazards Analysis* 
Variable Coefficient SE c2 P= 
BSP 0.0133 0.0054 6.382 0.0115 
MP 0.0937 0.0346 4.826 0.0280 
*All variables listed in Table 4 were included in the stepwise multivariate
regression analysis. Only those variables are presented that reached 
P values of <0.05. Abbreviations: see Table 1. Bone sialoprotein in multiple myeloma 351
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turnover and may be used to estimate the tumour burden and to
evaluate the effects of anti-myeloma and anti-resorptive (Woitge
et al, 1999) therapy. 
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